Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 46.9%

Neg 46.9% Neu 0% Pos 0%

Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $8 to $5.